Mixing Paradigms for More Comprehensible Models

Petri nets efficiently model both data- and control-flow. Control-flow is either modeled explicitly as flow of a specific kind of data, or implicit based on the data-flow. Explicit modeling of control-flow is useful for well-known and highly structured processes, but may make modeling of abstract features of models, or processes which are highly dynamic, overly complex. Declarative modeling, such as is supported by Declare and DCR graphs, focus on control-flow, but does not specify it explicitly; instead specifications come in the form of constraints on the order or appearance of tasks. In this paper we propose a combination of the two, using colored Petri nets instead of plain Petri nets to provide full data support. The combined approach makes it possible to add a focus on data to declarative languages, and to remove focus from the explicit control-flow from Petri nets for dynamic or abstract processes. In addition to enriching both procedural processes in the form of Petri nets and declarative processes, we also support a flow from modeling only abstract data- and control-flow of a model towards a more explicit control-flow model if so desired. We define our combined approach, and provide considerations necessary for enactment. Our approach has been implemented in CPN Tools 4

ASAP: An Extensible Platform for State Space Analysis

Abstract. The ASCoVeCo State space Analysis Platform (ASAP) is a tool for performing explicit state space analysis of coloured Petri nets (CPNs) and other formalisms. ASAP supports a wide range of state space reduction techniques and is intended to be easy to extend and to use, making it a suitable tool for students, researchers, and industrial users that would like to analyze protocols and/or experiment with different algorithms. This paper presents ASAP from these two perspectives.

An Ontology-Enabled Approach for Modelling Business Processes

International audienceColoured Petri Nets (CPNs) have formal semantics and can describe any type of workflow system, behavioral and syntax wise simultaneously. They are widely studied and successfully applied in modelling of workflows and workflow systems. There is an inherent problem regarding business processes modelled with CPNs sharing and subsequently their reuse need to be considered. The Semantic Web technologies, such as ontologies, with their characteristics demonstrate that they can play an important role in this scenario. In this paper, we propose an ontological approach for representing business models in a meta-knowledge base. Firstly, the CPN ontology is defined to represent CPNs with OWL DL. Secondly, we introduce four basic types of manipulation operations on process models used to develop and modify business workflow patterns. To the best of our knowledge, representing business process definitions and business workflow patterns as knowledge based upon ontologies is a novel approach

AD51B in Familial Breast Cancer

Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study was to investigate the role of RAD51B variants in breast cancer predisposition, particularly in the context of familial breast cancer in Finland. We sequenced the coding region of RAD51B in 168 Finnish breast cancer patients from the Helsinki region for identification of possible recurrent founder mutations. In addition, we studied the known rs999737, rs2588809, and rs1314913 SNPs and RAD51B haplotypes in 44,791 breast cancer cases and 43,583 controls from 40 studies participating in the Breast Cancer Association Consortium (BCAC) that were genotyped on a custom chip (iCOGS). We identified one putatively pathogenic missense mutation c.541C>T among the Finnish cancer patients and subsequently genotyped the mutation in additional breast cancer cases (n = 5259) and population controls (n = 3586) from Finland and Belarus. No significant association with breast cancer risk was seen in the meta-analysis of the Finnish datasets or in the large BCAC dataset. The association with previously identified risk variants rs999737, rs2588809, and rs1314913 was replicated among all breast cancer cases and also among familial cases in the BCAC dataset. The most significant association was observed for the haplotype carrying the risk-alleles of all the three SNPs both among all cases (odds ratio (OR): 1.15, 95% confidence interval (CI): 1.11–1.19, P = 8.88 x 10−16) and among familial cases (OR: 1.24, 95% CI: 1.16–1.32, P = 6.19 x 10−11), compared to the haplotype with the respective protective alleles. Our results suggest that loss-of-function mutations in RAD51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk

Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c

Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) are both used to diagnose diabetes, but these measurements can identify different people as having diabetes. We used data from 117 population-based studies and quantified, in different world regions, the prevalence of diagnosed diabetes, and whether those who were previously undiagnosed and detected as having diabetes in survey screening, had elevated FPG, HbA1c or both. We developed prediction equations for estimating the probability that a person without previously diagnosed diabetes, and at a specific level of FPG, had elevated HbA1c, and vice versa. The age-standardized proportion of diabetes that was previously undiagnosed and detected in survey screening ranged from 30% in the high-income western region to 66% in south Asia. Among those with screen-detected diabetes with either test, the age-standardized proportion who had elevated levels of both FPG and HbA1c was 29–39% across regions; the remainder had discordant elevation of FPG or HbA1c. In most low- and middle-income regions, isolated elevated HbA1c was more common than isolated elevated FPG. In these regions, the use of FPG alone may delay diabetes diagnosis and underestimate diabetes prevalence. Our prediction equations help allocate finite resources for measuring HbA1c to reduce the global shortfall in diabetes diagnosis and surveillance

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.</p